ACOR Acorda Therapeutics Inc.

16.18
+0.2  (+1%)
Previous Close 15.98
Open 15.78
Price To Book 1.28
Market Cap 769493925
Shares 47,558,339
Volume 463,794
Short Ratio
Av. Daily Volume 804,939

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
CVT-427
Migraine
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
Refuse-To-File letter August 30, 2017. New PDUFA date October 5, 2018 extended to January 5, 2018.
INBRIJA (CVT-301)
OFF episodes of Parkinson’s disease (PD)
Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.
BTT1023
Primary Sclerosing Cholangitis

Latest News

  1. Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
  2. Here's Why Acorda Therapeutics Shares Sunk 15% Today
  3. Acorda Launches Art Initiative to Foster Better Conversations About Parkinson’s Symptoms
  4. Should You Worry About Acorda Therapeutics Inc’s (NASDAQ:ACOR) CEO Pay?
  5. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  6. Acorda Down More Than 30% in the Past 3 Months: Here's Why
  7. Edited Transcript of ACOR earnings conference call or presentation 31-Oct-18 12:30pm GMT
  8. Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
  9. Acorda to Present at Stifel 2018 Healthcare Conference
  10. Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up
  11. Acorda Therapeutics Inc (ACOR) Q3 2018 Earnings Conference Call Transcript
  12. Acorda Therapeutics (ACOR) Q3 Earnings and Revenues Beat Estimates
  13. Acorda: 3Q Earnings Snapshot
  14. Acorda Provides Financial and Pipeline Update for Third Quarter 2018
  15. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
  16. Centene's (CNC) Earnings and Revenues Top Estimates in Q3
  17. Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries — Discovering Underlying Factors of Influence